Onosereme Ofoman

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Christina C. Chang, V. Naranbhai, A. Balazs, 2022, Cell.

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

B. Walker, V. Naranbhai, A. Balazs, 2022, Cell.

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Christina C. Chang, V. Naranbhai, A. Balazs, 2021, medRxiv.

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals

B. Walker, V. Naranbhai, A. Balazs, 2022, medRxiv.

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

B. Walker, V. Naranbhai, A. Balazs, 2022, Cell.

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

A. Iafrate, A. Bardia, H. Willers, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to SARS-CoV-2 Initial Series and Additional Dose Vaccine in Patients with Predominant Antibody Deficiency

Kristin E. Burke, A. Iafrate, S. Pillai, 2022, The Journal of Allergy and Clinical Immunology: In Practice.

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

A. Iafrate, A. Bardia, H. Willers, 2021, Cancer Cell.

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Christina C. Chang, V. Naranbhai, A. Balazs, 2021, Cell.